A Study of the Presillion Stent in de Novo Coronary Lesions (PRESILLION)
Primary Purpose
Coronary Artery Disease
Status
Completed
Phase
Phase 3
Locations
Belgium
Study Type
Interventional
Intervention
PRESILLION cobalt chromium stent
Sponsored by
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring Coronary Artery Disease
Eligibility Criteria
Inclusion Criteria:
- The patient must be >= 18 years of age.
- Patient is eligible for percutaneous coronary intervention (PCI).
- Acceptable candidate for coronary artery bypass surgery (CABG).
- Female patients of childbearing potential must have a negative pregnancy test within 7 days prior to enrolment and utilize reliable birth control for trial duration.
- Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) or unstable angina pectoris (Braunwald Classification B&C, I-II-III) or patients with documented silent ischemia.
- Treatment of up to two de novo native coronary artery lesions in a maximum of two major coronary arteries.
- Target reference vessel diameter of both lesions must be >= 2.5mm and <= 4.0mm in diameter (visual estimate).
- Target lesion length must be <= 30mm and be covered by one study stent.
- Target lesion stenosis for both lesions is > 50% and < 100% (visual estimate).
- At least TIMI I coronary flow.
- Patient is willing to comply with the specified follow-up evaluation.
- Patient must provide written informed consent prior to the procedure using a form that is approved by the local Ethics Committee.
Exclusion Criteria:
- Recent myocardial infarction (either STEMI or non STEMI < 48 hours prior to planned index procedure).
- The patient has unstable angina classified as Braunwald A I-II-III.
- The patient has unprotected left main coronary artery disease (stenosis >50%).
- A significant (> 50%) stenosis proximal or distal to the target lesion.
- Angiographic evidence of thrombus within the target lesion.
- Heavily calcified lesion and/or calcified lesion, which cannot be successfully predilated and/or an excessively tortuous vessel which makes it unsuitable for stent delivery and deployment.
- Left ventricular ejection fraction <= 25%.
- Totally occluded lesion (TIMI 0 level).
- The patient has impaired renal function (creatinine 3.0mg/dL) at the time of treatment.
- The patient had a Cerebrovascular Accident (CVA) within the past 6 months.
- Prior stent within 10mm of target lesion.
- The target lesion is ostial in location (within 3.0mm of vessel origin).
- The target lesion involves a bifurcation with a diseased (>50% stenotic) branch vessel >= 2.0mm in diameter (or side branch requiring intervention of protection).
- The target lesion is located in a bypass graft. Note: stenting of lesions in bypassed native coronary arteries is allowed.
- Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix ®) and ticlopidine (Ticlid ®), heparin, cobalt chromium, contrast agent (that cannot be managed medically).
- The patient has any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study.
- The patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the study endpoints.
- Intervention of another lesion within 30 days prior to, or is planned or highly probably to be performed 30 days after the index procedure.
Sites / Locations
- CHU de Liège
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
A
Arm Description
The PRESILLION TM Coronary Stent is an L-605 cobalt chromium (CoCr) stent.
Outcomes
Primary Outcome Measures
Composite of MACE which includes cardiac death, myocardial infarction (Q-wave and non Q-wave) and clinically driven target lesion revascularization (TLR).
Secondary Outcome Measures
Clinically driven Target Lesion Revascularization (TLR) defined as repeat PCI or CABG to the target lesion.
Clinically driven Target Vessel Revascularization (TVR) defined as repeat PCI or CABG to the target vessel.
Target Vessel Failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel.
Myocardial Infarction (MI).
Major bleeding.
Device success.
Lesion success.
Procedure success.
Incidence of acute and sub-acute stent thrombosis according the ARC definition.
Stroke.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00722579
Brief Title
A Study of the Presillion Stent in de Novo Coronary Lesions
Acronym
PRESILLION
Official Title
A Non-Randomized, Multi-Center, Single-Arm Safety Study of the Presillion Stent in de Novo Native Coronary Artery Lesions
Study Type
Interventional
2. Study Status
Record Verification Date
June 2010
Overall Recruitment Status
Completed
Study Start Date
July 2008 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
March 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Cordis Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The PRESILLION Study is a non-randomized, multi-center, single-arm study evaluating the safety of an approved Cobalt Chromium bare metal stent system for the treatment of ischemic heart disease attributable to a stenotic de novo lesion in a native coronary artery.
The study population will include 100 patients with up to two de novo native coronary artery lesions with a maximum lesion length of 30mm in a maximum of two major coronary arteries with reference vessel diameter >= 2.5mm and <= 4.0mm by visual estimation. Patients will be followed for 1 month and 6 month post-procedure for assessment of MACE and all other adverse events.
Detailed Description
The PRESILLION Stent System is intended for use in patients with symptomatic ischemic heart disease attributable to stenotic de novo lesions of native coronary arteries with reference vessel diameter from 2.5 mm to 4.0 mm with a lesion length up to 30 mm that are amenable to percutaneous treatment with coronary stenting. The stent is intended as a permanent implanted device.
The primary objective of this study is to evaluate the safety of the PRESILLION Stent System in the treatment of de novo stenotic lesions in native coronary arteries. The primary safety measure is the composite of MACE up to one (1) month follow up. The MACE rate shall meet the performance goal for bare metal stents in order to show the safety of the device.
The protocol has been amended and data will be collected for a time point as close as possible to (but after) the 6 months post index procedure in a non-interventional and retrospective manner. The data point will contain exactly the same follow-up information as was collected during the 1 month follow-up.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
Coronary Artery Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
101 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Arm Description
The PRESILLION TM Coronary Stent is an L-605 cobalt chromium (CoCr) stent.
Intervention Type
Device
Intervention Name(s)
PRESILLION cobalt chromium stent
Other Intervention Name(s)
bare-metal stent
Intervention Description
PTCA with bare-metal stent
Primary Outcome Measure Information:
Title
Composite of MACE which includes cardiac death, myocardial infarction (Q-wave and non Q-wave) and clinically driven target lesion revascularization (TLR).
Time Frame
1-month and 6-months post-procedure
Secondary Outcome Measure Information:
Title
Clinically driven Target Lesion Revascularization (TLR) defined as repeat PCI or CABG to the target lesion.
Time Frame
1-month and 6-months post-procedure
Title
Clinically driven Target Vessel Revascularization (TVR) defined as repeat PCI or CABG to the target vessel.
Time Frame
1-month and 6-months post-procedure
Title
Target Vessel Failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel.
Time Frame
1-month and 6-months post-procedure
Title
Myocardial Infarction (MI).
Time Frame
1-month and 6-months post-procedure
Title
Major bleeding.
Time Frame
1-month and 6-months post-procedure
Title
Device success.
Time Frame
Post-procedure
Title
Lesion success.
Time Frame
Post-procedure
Title
Procedure success.
Time Frame
Post-procedure
Title
Incidence of acute and sub-acute stent thrombosis according the ARC definition.
Time Frame
1-month and 6-months post-procedure
Title
Stroke.
Time Frame
Post-procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The patient must be >= 18 years of age.
Patient is eligible for percutaneous coronary intervention (PCI).
Acceptable candidate for coronary artery bypass surgery (CABG).
Female patients of childbearing potential must have a negative pregnancy test within 7 days prior to enrolment and utilize reliable birth control for trial duration.
Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) or unstable angina pectoris (Braunwald Classification B&C, I-II-III) or patients with documented silent ischemia.
Treatment of up to two de novo native coronary artery lesions in a maximum of two major coronary arteries.
Target reference vessel diameter of both lesions must be >= 2.5mm and <= 4.0mm in diameter (visual estimate).
Target lesion length must be <= 30mm and be covered by one study stent.
Target lesion stenosis for both lesions is > 50% and < 100% (visual estimate).
At least TIMI I coronary flow.
Patient is willing to comply with the specified follow-up evaluation.
Patient must provide written informed consent prior to the procedure using a form that is approved by the local Ethics Committee.
Exclusion Criteria:
Recent myocardial infarction (either STEMI or non STEMI < 48 hours prior to planned index procedure).
The patient has unstable angina classified as Braunwald A I-II-III.
The patient has unprotected left main coronary artery disease (stenosis >50%).
A significant (> 50%) stenosis proximal or distal to the target lesion.
Angiographic evidence of thrombus within the target lesion.
Heavily calcified lesion and/or calcified lesion, which cannot be successfully predilated and/or an excessively tortuous vessel which makes it unsuitable for stent delivery and deployment.
Left ventricular ejection fraction <= 25%.
Totally occluded lesion (TIMI 0 level).
The patient has impaired renal function (creatinine 3.0mg/dL) at the time of treatment.
The patient had a Cerebrovascular Accident (CVA) within the past 6 months.
Prior stent within 10mm of target lesion.
The target lesion is ostial in location (within 3.0mm of vessel origin).
The target lesion involves a bifurcation with a diseased (>50% stenotic) branch vessel >= 2.0mm in diameter (or side branch requiring intervention of protection).
The target lesion is located in a bypass graft. Note: stenting of lesions in bypassed native coronary arteries is allowed.
Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix ®) and ticlopidine (Ticlid ®), heparin, cobalt chromium, contrast agent (that cannot be managed medically).
The patient has any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study.
The patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the study endpoints.
Intervention of another lesion within 30 days prior to, or is planned or highly probably to be performed 30 days after the index procedure.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
V. Legrand, MD, Phd
Organizational Affiliation
CHU de Liège
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Liège
City
Liège
ZIP/Postal Code
B-4000
Country
Belgium
12. IPD Sharing Statement
Learn more about this trial
A Study of the Presillion Stent in de Novo Coronary Lesions
We'll reach out to this number within 24 hrs